- Количество слайдов: 37
Proposed Policy Topics for statement development by the APh. A Policy Committee Moderator: Bradley P. Tice, Pharm. D, MBA, FAPh. A Speaker, APh. A House of Delegates
For Your Information Please submit your thoughts on the policy topics throughout the webinar or send them to HOD@aphanet. org If you are using a phone line to listen, please dial 415 -655 -0062; Access Code: 856 -377 -400. Be sure to include your Audio PIN To request to speak, click on the raise hand tab and you will be placed in the queue. The comments we take or mention on the webinar may be limited due to time. However, all comments will be provided to the Policy Committee for use in their deliberations. The moderator will clarify issues but will not engage in debate. Remember, be courteous to your colleagues in your communications.
Goals 1. To provide an opportunity for member input on policy topics prior to the proposed statement development by the Policy Committee 2. To promote the early engagement of Delegates on the development and submission of quality new business items on topics not assigned to the Policy Committee 3. To generate Delegate interest in Policy and Houserelated committees as part of the policy development process
Objectives 1. Review the purpose of the House of Delegates 2. Review the policy development process 3. Review 2013 proposed policy topics and gain perspectives on the issues 4. Generate interest and solicit names for House Committees q Webinar scheduled for 90 minutes. q 10 minutes for intro, 20 minutes per topic, 20 minutes for final comments
Purpose of the House of Delegates & Association Policy • House of Delegates • “serves as a legislative body in the development of ASSOCIATION policy. It shall act on such policy recommendations as shall come before it and shall adopt rules or procedures for the conduct of its business. ” (from APh. A Bylaws) • Association Policy • • Advocacy Activities External Communications Advisory Committees Association Activities
APh. A House of Delegates Committees q House of Delegates Policy Committees q Policy Committee q Policy Review Committee q Policy Reference Committee q New Business Review Committee q House Rules Review Committee q House of Delegates Election Committees (every other year) q Committee on Nominations q Committee of Canvassers
APh. A House of Delegates by the Numbers 50 states plus DC, Guam, and Puerto Rico 12 National Pharmacy Organizations q AAPS, AACP, ACA, ACCP, AIHP, AMCP, ASHP, ASCP, ASPL, NCPA, National Pharmaceutical Association, National Pharmacists Association q 5 Federal Pharmacy Groups q Air Force, Army, Navy, PHS, VA q APh. A q Academies: APPM, APRS, ASP q Board of Trustees q Former Presidents q Former Speakers q q
Officers of the APh. A House of Delegates Bradley P. Tice, Pharm. D, MBA, FAPh. A Speaker, APh. A House of Delegates APh. A Board of Trustees William H. Riffee, Ph. D Speaker - Elect, APh. A House of Delegates Thomas E. Menighan, BS Pharm, MBA, Sc. D (Hon), FAPh. A Secretary, APh. A House of Delegates APh. A Executive Vice President & CEO APh. A Board of Trustees
Joint Policy Standing Committee Assignments q Topic Generation q. Ideas obtained from Delegates, Members, State Pharmacy Associations, Committees, Trustees, Staff, and Surveys q 43 topic submissions received q. Recommendations by APh. A-APPM/APRS/ASP Joint Policy Standing Committee q. Background on issues and potential direction assembled q. Topic Prioritization q. Committee discussed the top 15 topics q. Further discussed top 15, topics combined, and then ranked top 3 q. Refined direction of top 3 by answering key questions
Guidance to Joint Policy Standing Committee on each Topic q What is the problem? q Why is it a problem? q What are the issues that need to be addressed?
Top 3 Policy Topic Ideas 1. Expanding Access to Pharmaceuticals 2. Ensuring Access to Pharmacists’ Services (Role of payers and providers in Patient Care) 3. Medication Take Back/Disposal Programs
APh. A Pol. Transforming Ideas into Action State Associations GAC Surveys, Other APh. A Board of Trustees Webinar 3 APh. A Staff APh. AAPPM/APRS/ASP Joint Policy Standing Committee 2 APh. A Members 1 APh. A House of Delegates IDEA APh. A House of Delegates Policy Committee IDEA Implementation IDEAS For Policy Statements APh. A House of Delegates ADOPTED Policy Statements 4 ACTION PROPOSED Policy Statement YOU! 5 6 APh. A Board of Trustees APh. AAPPM/APRS/ASP Joint Policy Standing Committee Webinar
TOPIC 1: Expanding Access to Pharmaceuticals
Expanding Access to Pharmaceuticals Setting the stage Current drug classification system ▪ Rx and OTC (some state variances) ▪ Role / Involvement of pharmacists is variable ▪ Access by patients to some pharmaceuticals restricted ▪ Practice acts ▪ Insurance ▪ Access to care provider
Expanding Access to Pharmaceuticals Summary of Key Concepts Financial constraints / shortage of primary care physicians Growing interest in increasing access Pharmacists have knowledge / skills When pharmacists are more involved in patient care, health outcomes improve and costs go down. FDA is considering a new paradigm of medication use ▪ Reluctance among the physician community and some consumer groups that the new paradigm will sever the patient-physician relationship. Concern with use of vending machines, that are resulting in patients purchasing prescription and behind-the-counter medications without access to a pharmacist.
Expanding Access to Pharmaceuticals Potential Scope Supporting the creation of an “OTC+” or “Conditions of Safe Use” category of drugs which require pharmacist intervention Behind the counter and vending machine distribution of medications (EC) Stress importance of patients having access to beneficial medications and access to pharmacists’ services
Expanding Access to Pharmaceuticals What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language? Overall importance of patient access to pharmacists OTC+ ▪ Support opportunities for pharmacists to assume patient care roles, including OTC+ ▪ Support updating state and federal laws/regulations to require access to pharmacists ▪ Need some pilots ▪ Which prescription medications (or categories), if any, are appropriate for the OTC+ concept? ▪ What drug categories should be included; that we support the process, include monitoring and follow-up; could incorporate adherence for chronic disease medications. ▪ Opportunity to increase access and decrease cost ▪ Way to loop people back into the healthcare system (coordination and collaboration) ▪ Coordination with payers for payment and quality measures ▪ Way to improve quality ratings ▪ Address concerns raised by other health professions
Expanding Access to Pharmaceuticals What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language? How should vending machine distribution be controlled to ensure patient safety? ▪ Are there features that should be included (access to pharmacist? ) ▪ Are there medications that should not be distributed via this mechanism?
Expanding Access to Pharmaceuticals What are your thoughts?
TOPIC 2: Ensuring Access to Pharmacists’ Services (Role of payers and providers in Patient Care)
Ensuring Access to Pharmacists’ Services (Role of payers and providers in Patient Care) Potential Scope of Proposed Policy What is preventing pharmacists from performing medication therapy management (MTM) or other patient care services? Are there system issues impacting this? ▪ What is preventing payers from incentivizing or encouraging pharmacists to perform MTM or other patient care services? ▪ Are there practice issues creating barriers?
Ensuring Access to Pharmacists’ Services (Role of payers and providers in Patient Care) What Is The Problem? What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language? Health benefit data (medical and pharmacy) should be connected ▪ look at pharmacoeconomic and overall healthcare costs. Decisions need to be pursuant to evidence-based data CMS standards for MTM programs and contracting directly with providers
Ensuring Access to Pharmacists’ Services (Role of payers and providers in Patient Care) What Is The Problem? What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language? Others ▪ Prior authorization programs and formulary management policies can create barriers to patient care ▪ Payment to pharmacists by insurance and PBMs for medication management/patient care services ▪ PBM transparency ▪ Pharmacy overregulation ▪ Accountability of PBMs regarding the MTM benefit administration and the scope of benefits ▪ Provider status recognition and network inclusion
Ensuring Access to Pharmacists’ Services (Role of payers and providers in Patient Care) What are your thoughts?
TOPIC 3: Medication Take Back / Disposal Programs
Medication Take Back / Disposal Programs Potential Scope Pharmaceuticals and Personal Care Products in the Environments q Look at 2012 APh. A-ASP policy q Develop and implement standardized guidelines for the proper disposal of unused or expired medications that help prevent drug abuse and reduce harm to the environment. (Source: APh. A-ASP 2012. 3 – Proper Medication Disposal and Drug Take-Back Programs) Allow pharmacies to take back unused or expired medications, including controlled substances, through a process that minimizes diversion, liability, and financial burden to all stakeholders. (Source: APh. A-ASP 2012. 3 – Proper Medication Disposal and Drug Take-Back Programs) Encourage pharmacists and student pharmacists to serve as a source of information for the public on the proper disposal of unused or expired medications. (Source: APh. A-ASP 2012. 3 – Proper Medication Disposal and Drug Take-Back Programs)
Medication Take Back / Disposal Programs existing policy 2009 Medication Disposal 1. APh. A encourages appropriate public and private partnerships to accept responsibility for the costs of implementing safe medication disposal programs for consumers. Further, APh. A urges DEA to permit the safe disposal of controlled substances by consumers. 2. APh. A encourages provision of patient appropriate quantities of medication supplies to minimize unused medications and unnecessary medication disposal. (JAPh. A NS 49(4): 493 July/August 2009)
Medication Take Back / Disposal Programs What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language? Uniform disposal guidelines that align requirements for state and federal laws and regulations for pharmacists and patients Disposal of medications and hazardous pharmaceuticals and materials Safety in the household; lack of effective and available medication take back systems and programs in the community and through local pharmacies. Disposal guidelines and support for it. Should include public awareness of the issue. Take back guidelines (unit of use vs non-unit of use), liability issues, who should pay for the programs Address liability in relation to diversion by having policies and procedures, protection of public and the patient aspect of this Address pharmacist education on take back programs and environment Policies that are driving excess meds in environment (like 90 days supply, auto refills, etc) Re-use of meds returned Cost issues Ease take back program requirements through unit of use packaging
Medication Take Back / Disposal Programs existing policy 2012 Controlled Substances Regulation and Patient Care APh. A encourages the U. S. Department of Justice to collaborate with professional organizations to identify and reduce (a) the burdens on health care providers, (b) the cost of health care delivery, and (c) the barriers to patient care in the establishment and enforcement of controlled substance laws.
Medication Take Back / Disposal Programs existing policy 2006/2003 Unit-of-Use Packaging APh. A encourages the continued development, distribution and use of unit-ofuse packaging as the industry standard to enhance patient safety, patient compliance, and efficiencies in drug distribution.
Medication Take Back / Disposal Programs What are your thoughts?
2012 -13 APh. A Policy Review Committee Assignment Continue its review of the current APh. A Policy Manual by reviewing those statements last reviewed in 2008 (17 statements). The 2012 -13 APh. A Policy Review committee will review any current APh. A policy that may be affected by statements/topics proposed by the 2012 -13 APh. A Policy Committee Topics Include: Automation and Technology in Pharmacy Practice Automation and Technical Assistance Experiential Education Residency Programs Expansion and Recognition of Internship, Externship, and Clerkships Residencies in Community Pharmacy Schools' Curriculum and Contemporary Pharmacy Needs State Boards of Pharmacy/Inspections National Framework for Practice Regulation Sale of Home-use Diagnostic and Monitoring Products Prior Authorization Regulatory Compliance/Regulatory Burden Pharmacists' Role in the Development and Implementation of Disease-Based Clinical Guidelines Pharmacists and Ambulatory Patients Promotion of Pharmaceutical Care
Questions / Comments Opportunity to share additional thoughts or questions Remember, all comments will be provided to the Policy Committee for use in their deliberations. You may also send your comments to HOD@aphanet. org
Policy Development Next Steps Policy Committee Meeting q Sept 7 -9, 2012 q Webinar on proposed policy statements q January 2013 / February 2013 q q 2013 APh. A House of Delegates q Policy Reference Committee Open Hearing
Do you have a policy topic for the House? q New Business opportunity q. Forms available on website: www. pharmacist. com/hod q. For more information, Email: hod@aphanet. org
Thanks for your Attention! Questions
Thanks for your Attention! q This concludes our webinar. q Thank you for your participation and comments. q Questions / Comments q. Bradley P. Tice, Pharm. D, MBA, FAPh. A Speaker, APh. A House of Delegates Email: HOD@aphanet. org